Functionally, Jag1-ICD increases the migratory capacity of prostate cancer cells and enhances tumorigenic potential in vivo, indicating that Jag1-ICD contributes to the acquisition of an aggressive prostate cancer phenotype characterized by AR positivity, elevated CD133 expression, and enhanced self-renewal and survival properties [180] (Figure 2, right panel). Here, AR is linked to prostate cancer.